TD Cowen has reaffirmed its Buy rating on Amicus (NASDAQ:FOLD) Therapeutics (NASDAQ: FOLD) with a steady price target of $20.00.
The firm's analyst highlighted the recent intellectual property settlement between Amicus Therapeutics and TEVA Pharmaceuticals.
This agreement grants TEVA a non-exclusive, royalty-free license to produce a generic version of Galafold starting January 2037.
The settlement resolves ongoing uncertainty and provides clarity regarding the future revenue potential of Galafold, a key product in Amicus Therapeutics' portfolio.
The analyst from TD Cowen noted that this development is beneficial as it removes the overhang on Amicus Therapeutics' stock, potentially allowing for a smoother market performance going forward.
The analyst also expressed confidence that Amicus Therapeutics is likely to reach similar settlement agreements with other generic pharmaceutical manufacturers, specifically Aurobindo and Lupin. Such settlements would further secure the revenue stream from Galafold by establishing the terms under which generic versions can enter the market.
Galafold is used in the treatment of Fabry disease, a rare genetic disorder, and has been a significant contributor to Amicus Therapeutics' growth. The resolution of the IP litigation with TEVA is seen as a strategic move to protect this asset for an extended period.
In other recent news, Amicus Therapeutics has reached a significant settlement with Teva Pharmaceuticals, concluding a patent lawsuit over the drug Galafold. The agreement allows Teva to market a generic version of Galafold in the U.S. from January 30, 2037. This development has influenced BofA Securities to upgrade the stock target for Amicus from $13.00 to $15.00, maintaining a Buy rating.
Amicus reported a substantial revenue growth of 34%, reaching $127 million in the second quarter of 2024, largely due to Galafold's 19% surge in global sales. This performance led to an increase in the company's full-year revenue guidance to between 26-31%.
Investment banking firm Jefferies recently initiated coverage of Amicus, assigning a Buy rating to the company's stock. Jefferies projects that Amicus could engage in business development for a commercial rare disease drug in the next 12 to 18 months, a move expected to positively impact the company's earnings per share and drive margin expansion.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on Amicus Therapeutics' (NASDAQ:FOLD) financial position and market performance. The company's market capitalization stands at $3.52 billion, reflecting its position in the biotechnology sector. Amicus has shown strong revenue growth, with a 29.98% increase over the last twelve months as of Q2 2024, reaching $455.65 million. This growth aligns with the positive outlook on Galafold's revenue potential mentioned in the article.
InvestingPro Tips highlight that Amicus boasts impressive gross profit margins, which is crucial for a biotechnology company investing heavily in research and development. The company's gross profit margin of 89.88% for the last twelve months ending Q2 2024 underscores its ability to maintain profitability on its products, including Galafold.
Additionally, Amicus has seen a significant return over the last week, with a 13.05% price increase, possibly reflecting market optimism following the TEVA settlement. This short-term performance is complemented by a strong 15.13% return over the last three months, suggesting sustained investor confidence.
For readers interested in a more comprehensive analysis, InvestingPro offers 11 additional tips for Amicus Therapeutics, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.